Advances in prostate cancer in the last 10 years and a glimpse to the future
Nivolumab plus chemotherapy or ipilimumab vs chemotherapy as first-line treatment for gastric cancers
ESMO 2021: Latest in EGFR mutated advanced NSCLC
Trastuzumab deruxtecan vs trastuzumab emtansine in patients with HER2+ metastatic breast cancer
ESMO 2021: PARPi data and their role in mono/combination therapies
Radioembolisation with chemotherapy for colorectal liver metastases
ESMO 2021: Updates in hormone-sensitive prostate cancer
Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant NSCLC
ESMO 2021: Breast cancer roundup
Quality of life and safety in novel therapies for prostate cancer
[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally advanced or metastatic breast cancer
Enzalutamide plus androgen deprivation therapy prolongs survival in men with metastatic hormone-sensitive prostate cancer
